이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

InflaRx 관리

관리 기준 확인 2/4

InflaRx's CEO는 Niels Riedemann, Jan2007 에 임명되었습니다 의 임기는 17.42 년입니다. 는 $ 1.56M 가치에 해당하는 회사 주식의 1.82% 직접 소유합니다. 1.56M. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 5.1 년입니다.

주요 정보

Niels Riedemann

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	17.5yrs
CEO 소유권	1.8%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

Sep 29

InflaRx reports Q2 results

Aug 05

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Jul 26

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

Jul 16

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul 06

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

Jun 29

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Apr 01

Our First Look At InflaRx

Dec 29

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Dec 15

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 27

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

Aug 25

InflaRx initiates mid-stage vilobelimab skin cancer trial

Jun 08

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

May 01

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

Mar 02

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Jan 08

InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder

Jan 05

InflaRx reports Q3 results

Oct 29

CEO

Niels Riedemann (51 yo)

17.5yrs

테뉴어

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...

리더십 팀

이름	위치	테뉴어	보상	소유권
Niels Riedemann	Co-Founder	17.5yrs	데이터 없음	1.82% € 1.7m
Renfeng Guo	Co-Founder	17.5yrs	데이터 없음	2.99% € 2.9m
Thomas Taapken	Chief Financial Officer	3.8yrs	데이터 없음	0.0059% € 5.7k
Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance	1.3yrs	데이터 없음	데이터 없음
Camilla Chong	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Jan Medina	Head of Investor Relations & VP	less than a year	데이터 없음	데이터 없음
Christian Schmid	VP and Head of Legal Affairs & General Counsel	no data	데이터 없음	데이터 없음
Nicole Bertsch	Senior Director & Head of Human Resources	3.3yrs	데이터 없음	데이터 없음
Maria Habel	VP, Head of Preclinical R&D and QC	11.5yrs	데이터 없음	데이터 없음
Bruce Burnett	VP & Head of Medical Affairs	no data	데이터 없음	데이터 없음
Kofi Boaten	Senior Director and Head of Supply Quality & Clinical Trial Supplies	no data	데이터 없음	데이터 없음
Peter Hurt	Senior Director and Head of Drug Safety & Pharmacovigiliance	no data	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: IFRX 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Niels Riedemann	Co-Founder	no data	데이터 없음	1.82% € 1.7m
Renfeng Guo	Co-Founder	no data	데이터 없음	2.99% € 2.9m
Nicolas Fulpius	Independent Chairman of the Board	17.5yrs	데이터 없음	0.79% € 762.7k
K. Reinhart	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
P. Ward	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Brudnick	Independent Non-Executive Director	5.2yrs	데이터 없음	0.085% € 81.5k
Hege Hellstrom	Non-Executive Director	1.3yrs	데이터 없음	데이터 없음
Mark Kubler	Independent Non-Executive Director	9.5yrs	데이터 없음	1.63% € 1.6m
Anthony Gibney	Independent Non-Executive Director	3.2yrs	데이터 없음	0.017% € 16.3k

5.2yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: IFRX 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

InflaRx 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

InflaRx N.V., Annual General Meeting, Apr 25, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Co-Founder notifies of intention to sell stock

InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer

Recent updates

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

Consensus EPS estimates upgraded to €0.69 loss

New major risk - Revenue and earnings growth

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

Consensus revenue estimates fall by 94%

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Consensus revenue estimates fall by 13%

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

No longer forecast to breakeven

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates fall by 68%

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Consensus revenue estimates increase by 883%, EPS downgraded

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Consensus revenue estimates increase by 34%

Consensus revenue estimates increase by 34%

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx reports Q2 results

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

Consensus revenue estimates fall by 31%

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Our First Look At InflaRx

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Consensus forecasts updated

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

InflaRx initiates mid-stage vilobelimab skin cancer trial

Consensus revenue estimates increase to €1.05m

Inflarx Announces Positive Topline Results for Vilobelimab from the U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

Consensus forecasts updated